Drug Recalls and Quality Withdrawals
On this page
Direct answer
A batch of cough syrup fails laboratory testing — the machinery of drug recalls begins: the sample is declared not of standard quality (NSQ) or spurious by a Central or State Drugs Laboratory, the licence holder withdraws the batch from the market, and the risk level decides the clock. CDSCO recall guidelines (revised 2024) adopt a three-class system mirroring international practice — Class I for dangerous or defective products with serious health risk, completed within 24 hours (up to 72 at the outside); Class II within 10 days; Class III within 30 days — though the framework remains guideline-based, not a statutory recall law under the Drugs and Cosmetics Act, 1940. Market withdrawal for safety, distinct from batch recall, travels through pharmacovigilance — PvPI signal detection at IPC Ghaziabad leading to label changes, restrictions or licence suspension.
What you must remember
- Terminology that earns marks: an NSQ drug fails quality standards (wrong assay, dissolution, contamination); a spurious drug is deliberately misrepresented — fake identity, copied labels, or sold under another's name; an adulterated drug contains harmful substitution.
- Recall classes and clocks: Class I (serious risk — wrong ingredient, contaminated injectables): withdraw within 24 hours and notify authorities within 24 hours of awareness; Class II (temporary or medically reversible harm): up to 10 days; Class III (unlikely to cause harm — minor label defects): up to 30 days.
- Who acts: drug inspectors of State and Central authorities sample and seize; the Central Drugs Laboratory (Kolkata) is the appellate analyst; manufacturers bear primary recall responsibility — the federal split (most manufacture licensed by states) is the structural weakness examiners quote.
- Quality-tragedy anchors: diethylene glycol (DEG) and ethylene glycol contamination of cough syrups — the Gambia and Uzbekistan deaths of 2022 traced to Indian-manufactured syrups — drive excipient identity testing; DEG is metabolised to oxalic acid and causes acute kidney injury with cranial neuropathy.
- Recall versus withdrawal versus suspension: batch recall (one defective batch), market withdrawal (minor violation), safety withdrawal of the molecule (phenformin, rofecoxib, cisapride in India's own history), and licence suspension (regulatory punishment).
- Vigilance linkage: unexpected therapeutic failure or batch-clustered reactions should be reported to PvPI as suspected quality problems.
- Scale of the problem: recent CDSCO surveillance declares double-digit to low-hundreds NSQ samples monthly with single-digit spurious detections — on the order of 2-3 per cent NSQ of tested samples in recent years.
A worked recall walkthrough
A state drug inspector's routine sample of a paediatric paracetamol syrup returns "assay 62 per cent of label claim; fails dissolution." The declaration is NSQ, classified Class II — subtherapeutic analgesia in a child, temporary and reversible harm. The manufacturer halts distribution, retrieves the batch through stockists, publishes recall notices, and files effectiveness checks; the state licensing authority verifies, and CDSCO's monthly NSQ list carries the batch number publicly. Had the failure been DEG contamination, the classification jumps to Class I with a 24-hour clock — and probable criminal proceedings if misrepresentation is established.
The clinician's role: report the suspected batch to PvPI, retain the sample, and document the batch number in the case notes — pharmacovigilance and quality surveillance converge at the bedside.
How the exam frames it
Two stems dominate. The definitional one: distinguish NSQ from spurious from adulterated — the intent element separating spurious from merely substandard. The systems one: name the recall classes with their timelines (24 hours, 10 days, 30 days) and the CDSCO guideline basis, noting for the viva that India still lacks a statutory recall law, the framework operating through guidelines and the D&C Act's general powers. The toxicology crossover brings DEG: oxalic-acid metabolism, renal tubular and cranial-nerve injury, and the preventive pharmacopeial identity tests for glycols. Programme-level questions link recalls to PvPI reporting and the consumer-facing CDSCO NSQ notices.
Frequently asked questions
What is the difference between an NSQ and a spurious drug?
A not-of-standard-quality drug genuinely originates from its manufacturer but fails quality parameters (assay, dissolution, contamination), while a spurious drug is misrepresented — imitation identity, false labelling, or another's name — carrying far harsher penalties under the Drugs and Cosmetics Act.
What are the three recall classes and their timelines in India?
Class I (serious health risk) completes withdrawal within 24 hours, extendable to 72; Class II (temporary or reversible harm) within 10 days; Class III (unlikely to cause harm) within 30 days.
Why is diethylene glycol contamination of syrups lethal?
DEG is metabolised to oxalic and glycolic acids, producing acute tubular injury with anuric renal failure, metabolic acidosis and cranial neuropathy — deaths in Gambia and Uzbekistan in 2022 tightened excipient testing globally.
How does a clinician contribute to drug recall systems?
Report suspected quality failures — therapeutic failure, batch-clustered adverse events — to PvPI with the batch number retained, feeding the signal machinery that triggers testing and recall.
Does India have a statutory drug recall law?
Not a dedicated one; recalls operate under Drugs and Cosmetics Act powers plus CDSCO guidelines revised in 2024, and this guideline-based status is a recognised regulatory gap.